TABLE 2.
Sample data
| Patient ID | Diagnosis | Sample | Time/procedure | Chemotherapy received | AFP | Disease burden | CTC count (cells/mL)—standard | CTC count (cells/mL)—imaging | Histology | GPC3 score of clinical sample (I+E=T) |
|---|---|---|---|---|---|---|---|---|---|---|
| HB70/110 | HB | HB70 | Hepatectomy | N | 978 | Increasing | 31.80 | Mixed epithelial (mitotically inactive fetal, embryonal), mesenchymal HB | Epithelial 3+4=7 | |
| HB110 | Clinic | Y | 3.5 | Decreasing | 11.00 | Mesenchymal 1+1=2 | ||||
| HB73 | HB | HB73 | Biopsy | N | 207,000 | Increasing | 28.00 | Epithelial (mitotically inactive fetal, embryonal) HB | 2.5+4=7 | |
| HB77 | HB | HB77 | Hepatectomy | Y | 2931 | Decreasing | 26.62 | 36.47 | Epithelial (mitotically inactive fetal, embryonal), mesenchymal with teratoid | Epithelial 3+4=7 |
| HB78 | HB | HB78 | Biopsy | N | 161 | Increasing | 2.25 | 5.00 | Epithelial (mitotically inactive fetal) HB | 2+2=4 |
| HB80 | HB | HB80 | Hepatectomy | Y | 40 | Decreasing | 75.50 | 79.00 | Mixed epithelial (mitotically inactive fetal, embryonal), mesenchymal, teratoid HB | Epithelial 2+4=6 |
| HB99 | HB | HB99 | Metastasectomy | Y | 14 | Decreasing | 0.00 | Epithelial (mitotically inactive fetal, embryonal) HB | 2+3=5 | |
| HB102/106 | HB | HB102 | TARE | Y | >207,000 | Increasing | 7.03 | 0.00 | HCN, NOS | 2+2=4 |
| HB106 | Hepatectomy | Y | >207,000 | Increasing | 88.67 | 9.33 | ||||
| HB103/113 | HB | HB103 | Metastasectomy | Y | 52.6 | Increasing | 0.00 | 0.00 | Epithelial HB | 3+4=7 |
| HB113 | Metastasectomy | Y | 601 | Increasing | 21.00 | 18.00 | ||||
| HB108 | HB | HB108 | Transplant | Y | 195 | Decreasing | 7.50 | 11.50 | Epithelial HB | Not available |
| HB109 | HB | HB109 | Hepatectomy | N | 102,000 | Increasing | 254.00 | 231.00 | Epithelial (mitotically inactive fetal, embryonal) HB | 2+1=3 |
| HB112 | HB | HB112 | Hepatectomy | Y | 405 | Decreasing | 6.00 | 0.00 | Mixed epithelial (mitotically inactive fetal), mesenchymal, teratoid HB | Epithelial 3+4=7 |
| HB134 | HB | HB134 | Hepatectomy | Y | 101 | Decreasing | 0.00 | Epithelial, mesenchymal HB | Not available | |
| HB83/114/116 | HCC | HB83 | TARE | Y | >207,000 | Increasing | 7.50 | 10.00 | HCC | 3+4=7 |
| HB114 | Hepatectomy | Y | 10.5 | Decreasing | 0.20 | |||||
| HB116 | Metastasectomy | Y | 2.1 | Decreasing | 8.00 | |||||
| HB105 | FLC | HB105 | Metastasectomy | Y | NA | Increasing | 10.50 | FLC | 0+0=0 | |
| HB119 | FLC | HB119 | Biopsy | N | <.8 | Increasing | 54.04 | FLC | 0+0=0 | |
| HB71 | MH | HB71 | Hepatectomy | N | 33 | 1.20 | MH | 0+0=0 |
Note: CTC burden shown is the number of DAPI+/ICG+/GPC3+ cells measured by the indicated flow cytometry instrument.
Abbreviations: AFP, alpha-fetoprotein; CTC, circulating tumor cell; FLC, fibrolamellar carcinoma; GPC3, Glypican-3; HB, hepatoblastoma; HCN, hepatocellular neoplasm; MH, mesenchymal hamartoma; NA, not available; NOS, not otherwise specified; TARE, transarterial radioembolization.